BioStock: Evaxion Biotech gets a go-ahead for phase IIb with EVX-01

One of the big milestones coming for Danish Evaxion Biotech in 2022 is the phase IIb trial initiation with cancer immunotherapy EVX-01. The company has now received clearance from the Australian regulatory body, and the study is expected to start in the second quarter this year. BioStock reached out to Niels Iversen Møller, Co-founder and CBO, to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/evaxion-biotech-gets-a-go-ahead-for-phase-iib-with-evx-01/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se